Full text is available at the source.
Abstract
Inter-individual variation in response to glucagon-like peptide-1 receptor agonists (GLP-1RAs) may be influenced by gut microbiota composition.
- Certain gut microbes, including specific species and those producing short-chain fatty acids, are associated with enhanced efficacy of GLP-1RAs.
- Improved insulin sensitivity and stimulation of endogenous GLP-1 secretion may result from beneficial microbial populations.
- Dysbiosis, characterized by reduced microbial diversity and increased pro-inflammatory bacteria, correlates with poor response to GLP-1RAs.
- GLP-1RAs might also have positive effects on gut microbiota, suggesting a bidirectional relationship.
- The interaction between GLP-1RAs and gut microbiota presents a novel interface that could inform precision medicine in diabetes treatment.
Simplified